Recursion Pharmaceuticals (RXRX) Accounts Payables (2020 - 2026)

Recursion Pharmaceuticals (RXRX) has 7 years of Accounts Payables data on file, last reported at $20.3 million in Q1 2026.

• Quarterly Accounts Payables fell 18.89% year-over-year to $20.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $20.3 million (down 18.89% YoY) and the FY2025 annual result came in at $18.1 million, down 16.17% from the prior year.
• Accounts Payables grew to $20.3 million in Q1 2026, from $18.1 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $25.1 million in Q1 2025 to a low of $2.1 million in Q2 2023.
• A 5-year average of $9.4 million and a median of $4.3 million in 2023 frame the typical range for Accounts Payables.
• Annual changes were most pronounced in 2024 — Accounts Payables plunged 47.01% — and 2025, when it soared 516.59%.
• Tracing RXRX's Accounts Payables over 5 years: stood at $4.6 million in 2022, then decreased by 13.8% to $4.0 million in 2023, then jumped by 446.75% to $21.6 million in 2024, then retreated by 16.17% to $18.1 million in 2025, then increased by 12.31% to $20.3 million in 2026.
• The last three Accounts Payables figures came in at $20.3 million (Q1 2026), $18.1 million (Q4 2025), and $13.9 million (Q3 2025), per Business Quant data.